Evidence map›Paper›PMID 25874011›Full record

ArticleJournal of Cancer2015

Role of mitochondrial network stabilisation by a human small heat shock protein in tumour malignancy.

Zsuzsanna Turi, Eniko Hocsak, Boglarka Racz, Aliz Szabo, Andras Balogh, Balazs Sumegi, Ferenc Gallyas

Abstract read
In one paragraph

Article in Journal of Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Dynamins and BAR Proteins-Safeguards against Cancer.Critical reviews in oncogenesis · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zsuzsanna Turi1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary;
Eniko Hocsak1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary;
Boglarka Racz1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary;
Aliz Szabo1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary;
Andras Balogh2. Department of Medical Biology , University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary;
Balazs Sumegi1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary; ; 3. MTA-PTE Nuclear-Mitochondrial Interactions Research Group, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary; ; 4. Szentagothai Research Centre, 34 Ifjusag St., H-7624 Pécs, Hungary.
Ferenc Gallyas1. Department of Biochemistry and Medical Chemistry, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary; ; 3. MTA-PTE Nuclear-Mitochondrial Interactions Research Group, University of Pécs Medical School, 12 Szigeti St., H-7624 Pécs, Hungary; ; 4. Szentagothai Research Centre, 34 Ifjusag St., H-7624 Pécs, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we found that the unconventional small human heat-shock protein HSPB11 inhibits cell death by HSP90 mediated cholesterol-rich membrane microdomain dependent activation of phosphatidylinositol-3 kinase/protein kinase B pathway and by stabilising the mitochondrial membrane systems. Also, progressive cytoplasmic expression of HSPB11 correlated with brain tumor malignancy. In the present study we investigated how cytoplasmic abundance of HSPB11 augments tumor malignancy. We up- and downregulated the cytoplasmic level of HSPB11 before paclitaxel exposure in NIH3T3 and HeLa cells, which normally express low and high levels, respectively, of the HSPB11 protein. We examined the paclitaxel-mediated induction of cell death, mitochondrial fission, HSPB11 mitochondrial translocation and inhibitory phosphorylation of dynamin-like protein-1 (DLP1). We found that increasing cytoplasmic abundance of HSPB11 in NIH3T3 cells protected against paclitaxel-induced apoptosis, while suppressing HSPB11 in HeLa cells sensitised the cells toward paclitaxel. Also, paclitaxel enhanced mitochondrial translocation of HSPB11 in wild type HeLa but not in NIH3T3 cells. More importantly, increased cytoplasmic level of HSPB11 in NIH3T3 cells enhanced the inhibitory phosphorylation of DLP1 and attenuated paclitaxel-induced mitochondrial fission. All these results suggest that increased cytoplasmic abundance of HSPB11 augments inhibitory phosphorylation of DLP1 thereby reduces mitochondrial fission that eventually leads to decreased apoptosis. This novel mechanism may explain the resistance to apoptosis and increased malignancy of HSPB11-overexpressing tumours. The clinical significance of this mechanism has already been highlighted by the finding that the kinase inhibitor tyrphostin A9 induces cancer cell death by DLP1-mediated mitochondrial fragmentation.

Indexed as

apoptosiscytoprotectionDLP1HeLaHSPB11mitochondrial fissionsHSPtumour malignancy.

Identifiers

PMID25874011
PMCPMC4392056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.